The investment seeks daily investment results, before fees and expenses, of 300% of the inverse of the daily performance of the S&P Biotechnology Select Industry Index... Show more
LABD, officially the Direxion Daily S&P Biotech Bear 3X ETF, is a specialized exchange-traded fund built for traders who want aggressive, short-term "bearish" exposure to the U.S. biotechnology sector. Rather than investing in biotech companies to benefit from their success, LABD is engineered to rise when biotechnology stocks fall—and to do so at three times the magnitude of the daily move.
This makes LABD very different from a conventional ETF. It is a trading instrument, not a long-term portfolio building block. Investors follow it for its leverage, its inverse exposure, and its role in hedging or speculating on short-term moves in one of the stock market's most volatile sectors.
LABD seeks daily investment results, before fees and expenses, of 300% of the inverse (the opposite) of the daily performance of the S&P Biotechnology Select Industry Index. In practical terms, if that index declines 1% in a single trading day, the fund aims to gain roughly 3%; if the index rises 1%, the fund aims to lose roughly 3%.
The underlying index is a modified equal-weighted benchmark designed to measure the performance of the biotechnology sub-industry, as classified under the Global Industry Classification Standard (GICS). Because it is equal-weighted rather than market-cap-weighted, the index gives proportionally more weight to smaller and mid-sized biotech companies than a cap-weighted benchmark would, which contributes to its historically higher volatility.
LABD is a passively managed fund that pursues its leveraged inverse objective through derivatives. Under normal circumstances, the fund invests at least 80% of its net assets in financial instruments—including swap agreements, futures contracts, and short positions—that, in combination, provide 3X daily inverse exposure to the index. As a result, its actual portfolio holdings consist mainly of cash, U.S. Treasury instruments, and money-market funds used as collateral, alongside the swap and short positions that generate the inverse returns. Reported holdings commonly include institutional cash-management and Treasury funds from firms such as Goldman Sachs and BNY Mellon (Dreyfus).
The fund is issued by Direxion, a firm known for leveraged and inverse ETFs, and is managed by Rafferty Asset Management, LLC. LABD carries an expense ratio of roughly 1% (approximately 0.95% to 1.07%, depending on the reporting period), which is typical for leveraged products but higher than plain-vanilla index ETFs. It is non-diversified, meaning it can concentrate its positions more heavily than a diversified fund.
LABD attracts attention primarily because of its leverage and its inverse sector exposure. Biotechnology is a uniquely volatile corner of the market, where individual drug approvals, clinical trial results, and regulatory decisions can move entire indices sharply in a single session. For traders with a bearish short-term view on biotech, LABD offers a way to amplify that view without shorting individual stocks.
The fund also serves a hedging role. An investor with broad biotechnology holdings might use a small, temporary position in LABD to help offset short-term declines. Its heavily traded nature and its pairing with the bullish LABU give traders a readily available way to express views in both directions. The same underlying index is tracked by well-known unleveraged funds such as the SPDR S&P Biotech ETF (XBI), which some traders reference for context on the sector's broader market position and portfolio holdings.
LABD is among the riskier products available to individual investors, and its key risks stem directly from its design:
Direxion itself cautions that leveraged and inverse ETFs are not suitable for all investors and should generally be used only by those who understand leverage risk and actively manage their positions.
Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to surface ideas that match their own investment strategies—including leveraged and inverse products like LABD. Explore the AI Screener to see how it can help refine your research workflow.
LABD occupies a distinct niche in the ETF landscape. It offers traders a liquid, leveraged way to bet against the daily direction of U.S. biotechnology stocks, a sector known for sharp swings. Its value lies in short-term tactical use—whether for speculation or temporary hedging—rather than as a long-term holding. For investors who understand its daily-reset mechanics and accept its elevated risk, LABD remains a widely used tool for navigating one of the market's most dynamic industries.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.